tbuckley/cabot-search huggingface dataset:
BMET-07SURVIVAL PATTERNS OF PATIENTS WITH CEREBRAL METASTASES WHO UNDERWENT MULTIPLE ROUNDS OF STEREOTACTIC RADIOSURGERY (SRS)
Authors: Deborah Marshall, Logan Marcus, Brandon McCutcheon, Steve Goetsch, John Alksne, Kenneth Ott, Bob Carter, Jona Hattangadi, Takao Koiso, Masaki Yamamoto, Clark Chen
Journal: Neuro-Oncology (2015)

OBJECT: With escalating focus on cost containment, there is increasing scrutiny on the practice of multiple-rounds of stereotactic radiosurgery (SRS) for patients with cerebral metastases distant to the initial tumor site. A major concern is that such recurrence may be a prognostic indicator of poor overall survival. METHODS: We retrospectively analyzed survival outcomes of 801 patients with 3683 cerebral metastases from primary breast, colorectal, lung, melanoma and renal histologies consecutively treated at the University of California, San Diego/San Diego Gamma Knife Center (UCSD/SDGKC), comparing the survival pattern of patients who underwent a single-round (n = 643) versus multiple rounds of SRS (n = 158) for subsequent cerebral metastases. Findings were recapitulated in an independent cohort of 2472 patients, with 26,629 brain metastases treated with SRS at the Katsuta Hospital Mito GammaHouse (KHMGH). RESULTS: For the UCSD/SDGKC cohort, no significant difference in median survival was found for patients undergoing 1, 2, 3, or >4 rounds of SRS (median survival of 167, 202, 129, and 127 days, respectively). Median intervals between treatments consistently ranged 140-178 days irrespective of rounds of SRS (interquartile range 60-300; p = 0.25). Patients who underwent >1 rounds of SRS tend to be younger, with systemic disease control, harbor lower cumulative tumor volume but increased number of metastases (p < 0.001, <0.001, <0.001, and 0.02, respectively). Comparable results were found in the KHMGH cohort. CONCLUSIONS: Using a cross-institutional validation study design, we demonstrated comparable overall survival between judiciously selected patients who underwent single or multiple rounds of SRS. The results suggest that select brain metastasis patients can benefit from up to four rounds of SRS.
MYELOKENTRIC ACID IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
Authors: M M SWAN, S ZELMAN
Journal: Annals of Internal Medicine (1950)

Case Reports1 August 1950MYELOKENTRIC ACID IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIAM. M. SWAN, Ph.D., M.D., SAMUEL ZELMAN, M.D., F.A.C.P.M. M. SWAN, Ph.D., M.D.Search for more papers by this author, SAMUEL ZELMAN, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-33-2-438 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMiller and his co-workers1 have reported remissions produced in eight cases of acute lymphoblastic leukemia by the parenteral use of extracts of urine or stools from patients with chronic myeloid leukemia. The opportunity was recently afforded us of carrying out such therapy in a case of lymphoblastic leukemia that was hospitalized at a time when a patient with chronic myeloid leukemia was available. The result proved of considerable interest, and tends to confirm the findings of the aforementioned investigators.The urine extract was prepared as described by Miller and Hause.2A chloroform extract of acid-hydrolyzed urine was evaporated, reconstituted as...Bibliography1. MillerHerbutJones FRPAHW: The treatment of lymphoblastic leukemia with crude myelokentric acid, Blood 2: 15, 1947. CrossrefMedlineGoogle Scholar2. MillerHause FRWA: Specific substances in the urine of leucemia patients, Proc. Soc. Exper. Biol. and Med. 45: 387, 1940. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Topeka, Kansas*Received for publication June 9, 1949.From the Medical Service, Winter Veterans Administration Hospital, Topeka, Kansas.Published with permission of the Chief Medical Director, Department of Medicine and Surgery, Veterans Administration, who assumes no responsibility for the opinions expressed or conclusions drawn by the authors.†Prepared for us by Mr. Theodore Gilbert, of the Biochemical Laboratory, Winter Veterans Administration Hospital. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byClinical studies on anticancer agents from 1949 to 1951 1 August 1950Volume 33, Issue 2Page: 438-442KeywordsChronic myeloid leukemiaHospital medicineMedical servicesPrecursor cellsResearch laboratoriesSurgeryUrine ePublished: 1 December 2008 Issue Published: 1 August 1950 PDF downloadLoading ...
Functional Assessment of Bioprosthetic Aortic Valves by CMR
Authors: Dimitrios Maragiannis, Matthew S. Jackson, Jose H. Flores-Arredondo, Kyle Autry, Robert C. Schutt, Paulino A. Alvarez, William A. Zoghbi, Dipan J. Shah, Stephen H. Little
Journal: JACC. Cardiovascular imaging (2016)
Abstract 11975: The Burden of Heart Failure Related Hospitalizations in Children with Single Ventricle Heart Disease in the United States
Authors: Joseph W Rossano, David J Goldberg, Antonio R Mott, J W Gaynor, Kimberly Y Lin, Christine B Falkensammer, Robert E Shaddy, Beth D Kaufman, Jack Rychik
Journal: Circulation (2012)

Introduction: As more children survive palliation of single ventricle heart disease (SVHD), many have co-morbid heart failure. However, few data exist on heart failure in this population. Hypothesi...
Adenocarcinoma of The Kidney. III. Histogenesis of Renal Adenocarcinomas Induced in Rats by N-(4′-Fluoro-4-biphenylyl)acetamide234
Authors: Jane H. Qees, Barry M. Heatfield, Melvin D. Reuber, Benjamin F. Trump
Journal: JNCI Journal of the National Cancer Institute (1980)

The histogenesis of renal adenocarcinoma induced in F344 rat. by the carcinogen N-(4′-fluoro-4-biphenylyl)acetemlde (FBPA) wa. described in order to clarify the site of origin of this neoplasm within the nephron. FBPA was added to the diet up to 48 weeks, and the animals were killed at intervals from 4 to 52 weeks after initiation of the carcinogenic diet. As seen by light microscopy, tumors appeared to arise from the pars recta of the proximal tubule in a series of stages progressing from focal hyperplasia with dysplasia to development of small, then large, neoplastic nodules composed of moderately basophilic, closely packed tumor cells arranged in individual aggregates or lobules surrounded by basement membrane-like material. Karyomegaly, cystic lesions, foam cell lesions, interstitial fibrosis, and casts also accompanied tumorigenesis in this animal model.
Questions about clinical trials in hypercalcemia.
Authors: R P Warrell
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.5.759 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3284973 Questions about clinical trials in hypercalcemia. R P Warrell JrxR P Warrell JrSearch for articles by this author https://doi.org/10.1200/JCO.1988.6.5.759 First Page PDF © 1988 by American Society of Clinical Oncology
Use of Very Small Embryonic-Like Stem Cells to Avoid Legal, Ethical, and Safety Issues Associated With Oncofertility
Authors: Deepa Bhartiya
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Prognostic factors for colon cancer.
Authors: S S Ellenberg, R J Mayer, H E Lessner
Journal: Journal of Clinical Oncology (1988)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1988.6.6.1066 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3373262 Prognostic factors for colon cancer. S S EllenbergxS S EllenbergSearch for articles by this author , R J MayerxR J MayerSearch for articles by this author , H E LessnerxH E LessnerSearch for articles by this author https://doi.org/10.1200/JCO.1988.6.6.1066 PDF "Prognostic factors for colon cancer.." Journal of Clinical Oncology, 6(6), pp. 1066–1067© 1988 by American Society of Clinical Oncology
Chronic Myelomonocytic Leukemia With Preexisting Myelodysplastic Syndrome Or Myeloproliferative Neoplasm: Two Stages Of One Disease With Poor Prognosis
Authors: Yin Xu, Aine Yung, Brian Kwok, Karen Macdonell, Bashar Dabbas, Prashanti Reddy
Journal: Blood (2013)
Weekend specialist intensity and admission mortality in acute hospital trusts in England: a cross-sectional study
Authors: Cassie Aldridge, Julian Bion, Amunpreet Boyal, Yen-Fu Chen, Mike Clancy, Tim Evans, Alan Girling, Joanne Lord, Russell Mannion, Peter Rees, Chris Roseveare, Gavin Rudge, Jianxia Sun, Carolyn Tarrant, Mark Temple, Sam Watson, Richard Lilford
Journal: The Lancet (2016)

BackgroundIncreased mortality rates associated with weekend hospital admission (the so-called weekend effect) have been attributed to suboptimum staffing levels of specialist consultants. However, evidence for a causal association is elusive, and the magnitude of the weekend specialist deficit remains unquantified. This uncertainty could hamper efforts by national health systems to introduce 7 day health services. We aimed to examine preliminary associations between specialist intensity and weekend admission mortality across the English National Health Service.MethodsEligible hospital trusts were those in England receiving unselected emergency admissions. On Sunday June 15 and Wednesday June 18, 2014, we undertook a point prevalence survey of hospital specialists (consultants) to obtain data relating to the care of patients admitted as emergencies. We defined specialist intensity at each trust as the self-reported estimated number of specialist hours per ten emergency admissions between 0800 h and 2000 h on Sunday and Wednesday. With use of data for all adult emergency admissions for financial year 2013–14, we compared weekend to weekday admission risk of mortality with the Sunday to Wednesday specialist intensity ratio within each trust. We stratified trusts by size quintile.Findings127 of 141 eligible acute hospital trusts agreed to participate; 115 (91%) trusts contributed data to the point prevalence survey. Of 34 350 clinicians surveyed, 15 537 (45%) responded. Substantially fewer specialists were present providing care to emergency admissions on Sunday (1667 [11%]) than on Wednesday (6105 [42%]). Specialists present on Sunday spent 40% more time caring for emergency patients than did those present on Wednesday (mean 5·74 h [SD 3·39] vs 3·97 h [3·31]); however, the median specialist intensity on Sunday was only 48% (IQR 40–58) of that on Wednesday. The Sunday to Wednesday intensity ratio was less than 0·7 in 104 (90%) of the contributing trusts. Mortality risk among patients admitted at weekends was higher than among those admitted on weekdays (adjusted odds ratio 1·10, 95% CI 1·08–1·11; p<0·0001). There was no significant association between Sunday to Wednesday specialist intensity ratios and weekend to weekday mortality ratios (r −0·042; p=0·654).InterpretationThis cross-sectional analysis did not detect a correlation between weekend staffing of hospital specialists and mortality risk for emergency admissions. Further investigation is needed to evaluate whole-system secular change during the implementation of 7 day services. Policy makers should exercise caution before attributing the weekend effect mainly to differences in specialist staffing.FundingNational Institute for Health Research Health Services and Delivery Research Programme.
Lipid Analyses of Isolated Plasma Membranes of Lymphoid Cells in Benign Thymomas of Bufffalo/Mna Rats23
Authors: Kinya Koizumi, Satoru Shimizu, Keiko Nishida, Keiko T. Koizumi, Naoki Yamanaka, Kazuo Ota, Mutsushi Matsuyama
Journal: JNCI Journal of the National Cancer Institute (1980)

Plasma membranes were isolated from lymphoid cells of benign thymomas obtained from inbred BUF/Mna rats (21 mo old) and from normal thymocytes obtained from young rats (7 wk old) of the same strain. The isolated plasma membranes were electron microscopically pure, and the specific activities of Na+, K+-ATPase, and 5'-nucleotidase were enhanced. The lipid compositions of the plasma membranes from these two sources were analyzed and compared. The cholesterol and plasmalogen contents of membranes from both sources were similar, but the phospholipid content of the benign thymoma lymphoid cell membranes was slightly lower than that of the normal thymocytes, resulting in a somewhat higher molar ratio of cholesterol to phospholipid. The plasma membranes of the thymoma lymphoid cells also exhibited a slightly higher microviscosity as measured with fluorescence polarization. No significant differences were observed in the phospholipid compositions of the two membrane preparations.
Impact of exercise selection on hamstring muscle activation
Authors: Matthew N Bourne, Morgan D Williams, David A Opar, Aiman Al Najjar, Graham K Kerr, Anthony J Shield
Journal: British Journal of Sports Medicine (2016)

To determine which strength training exercises selectively activate the biceps femoris long head (BFLongHead) muscle.We recruited 24 recreationally active men for this two-part observational study. Part 1: We explored the amplitudes and the ratios of lateral (BF) to medial hamstring (MH) normalised electromyography (nEMG) during the concentric and eccentric phases of 10 common strength training exercises. Part 2: We used functional MRI (fMRI) to determine the spatial patterns of hamstring activation during two exercises which (1) most selectively and (2) least selectively activated the BF in part 1.Eccentrically, the largest BF/MH nEMG ratio occurred in the 45° hip-extension exercise; the lowest was in the Nordic hamstring (Nordic) and bent-knee bridge exercises. Concentrically, the highest BF/MH nEMG ratio occurred during the lunge and 45° hip extension; the lowest was during the leg curl and bent-knee bridge. fMRI revealed a greater BF(LongHead) to semitendinosus activation ratio in the 45° hip extension than the Nordic (p<0.001). The T2 increase after hip extension for BFLongHead, semitendinosus and semimembranosus muscles was greater than that for BFShortHead (p<0.001). During the Nordic, the T2 increase was greater for the semitendinosus than for the other hamstring muscles (p≤0.002).We highlight the heterogeneity of hamstring activation patterns in different tasks. Hip-extension exercise selectively activates the long hamstrings, and the Nordic exercise preferentially recruits the semitendinosus. These findings have implications for strategies to prevent hamstring injury as well as potentially for clinicians targeting specific hamstring components for treatment (mechanotherapy).
Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva
Authors: K. S. Albain, S. Nag, G. Calderillo-Ruiz, J. P. Jordaan, A. Llombart, A. Pluzanska, M. Pawlicki, A. S. Melemed, J. O'Shaughnessy, J. M. Reyes
Journal: Journal of Clinical Oncology (2004)

510 Background: GT had phase II safety and efficacy in MBC after anthracyclines, so it was compared to T in a phase III study of frontline therapy. Accrual goals were met in 4/02 and at initial planned interim analysis, GT significantly improved time to progression (TTP), progression-free survival (PFS), objective response rates (ORR) and quality of life, with an acceptable toxicity profile (PASCO 22:161, 2003). It was uncertain if this would translate into overall survival (OS) benefit, the primary endpoint of the trial. This report presents the first OS analysis. Methods: Patients (pts) with measurable MBC, prior (neo)adjuvant anthracyclines and KPS ≥70 were randomized to GT (G 1250 mg/m2 d1,8; T 175 mg/m2 d1) or T (175 mg/m2 d1) q21 days to progression. With median follow-up of 15.6 mos (all but 1 pt off study), the first OS analyses by Kaplan-Meier and Cox regression were conducted at approximately 75% (343) of the deaths needed (440) for the planned final OS report. (All p-values are 2-sided; confidence intervals, 95%.) Results: Characteristics of the 529 eligible pts (267 GT, 262 T) with visceral-dominant disease; toxicity; and the significant benefit from GT in ORR, TTP and PFS were previously reported (ref. above). 38% on GT stopped therapy due to progression vs 55% on T; therapy ended due to adverse events in 6.7%, GT vs 5.0%, T. The OS hazard ratio (HR) was 0.775 (.627, .959) in favor of GT, p=.018. Median OS for GT was 18.5 mos (16.5–21.2) vs T, 15.8 mos (14.4–17.4). One-year survival was 70.7% (65.1–76.3%) for GT and 60.9% (54.8–66.9%) for T (p=.019). The HR in favor of GT persisted in Cox regression after adjusting for baseline covariates: 0.740 (.598, .915), p=.006. Second-line therapy was nearly identical between arms, except for a 4-fold greater use of gemcitabine in the T arm. Conclusions: GT provides significant OS advantage over T when both are given on a q3 week cycle, a result to be confirmed in the final planned analysis in late 2004. The TTP benefit predicted OS improvement with longer follow-up. GT should be considered a frontline regimen in MBC. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Eli Lilly Eli Lilly Eli Lilly
Effects of stem cell factor (kit-ligand) and interleukin-3 on the growth and serine proteinase expression of rat bone-marrow-derived or serosal mast cells
Authors: DM Haig, JF Huntley, A MacKellar, GF Newlands, L Inglis, R Sangha, D Cohen, A Hapel, SJ Galli, HR Miller
Journal: Blood (1994)
Ethics in Clinical Development
Authors: Peter J Keen
Journal: Journal of the Royal Society of Medicine (1990)

The meeting was convened to provide a forum for the discussion of those aspects of medical ethics which concerned clinical research, particularly the clinical studies which the pharmaceutical industry is required to carry out to satisfy regulatory authorities for them to issue licences for the introduction of new medicines. While the speakers did not confine themselves to this topic, they did raise many issue which impinge on clinical research with medicines, It is unfortunate that the meeting coincided with a server storm which undoubtedly restricted the audience and, therefore, the discussion which was intended. However, those who attended were fortunate to hear three excellent speakers give their personal views on an important subject which tends to be the Cinderella topic among clinical researchers and the pharmaceutical industry. However, all three speakers made the audience aware of the significance of ethics in all research on humans and the need for more education of both the profession and the public on this subject.
BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study
Authors: Jeremy S. Abramson, Kristie A. Blum, Ian W. Flinn, Martin Gutierrez, Andre Goy, Michael Maris, Michael Cooper, Michael O'Meara, Darrell Borger, Jennifer Mertz, Robert J. Sims, Supko Jeffrey, Anas Younes
Journal: Blood (2015)
Carbohydrate Antigen 19-9 Levels Associated with Pathological Responses to Preoperative Chemoradiotherapy in Rectal Cancer
Authors: S. Yeo, D.Y. Kim, T.H. Kim, S.Y. Kim, J.Y. Baek, H.J. Chang, J.W. Park, J.H. Oh
Journal: Annals of Oncology (2014)
Abstract #835: First bivalent fully antagonist anti-c-Met antibody targeting the c-Met receptor: I) in vitro mechanism of action
Authors: Nathalie Corvaïa, Alexandra Gonzalez, Nicolas Boute, Charlotte Beau-Larvor, Stéphanie Fabre-Lafay, Fabien Géronimi, Matthieu Broussas, Anne-Marie Lepecquet, Alain Robert, Thierry Wurch, Jean-François Haeuw, Christian Bailly, Liliane Goetsch
Journal: Cancer Research (2009)

c-Met is the prototypic member of a sub-family of receptor tyrosine kinases (RTK) which also includes RON and SEA. The c-Met RTK family is structurally different from other RTK families and is the only known high-affinity receptor for hepatocyte growth factor (HGF), also called scatter factor (SF). HGF and c-Met are widely expressed in a variety of tissues and their expression is normally restricted to cells of epithelial and mesenchymal origin, respectively. They are both required for normal mammalian development and have been shown to be particularly important for cell migration, morphogenic differentiation and organization of the three-dimensional tubular structures as well as cell growth and angiogenesis. While the controlled regulation of c-Met and HGF are essential for in mammalian development, tissue maintenance and repair, their deregulation is implicated in the progression of cancers. Aberrant signalling of c-Met can arise by ligand-dependent and independent mechanisms such as over-expression of c-Met, paracrine or autocrine activations, or through gain of function mutations. However, an oligomerization of the c-Met receptor, either in the presence or absence of the ligand, is required to regulate the binding affinity and binding kinetics of the kinase toward ATP and tyrosine-containing peptide substrates. An inappropriate c-Met activation plays a crucial role in tumorigenesis and metastasis. We have generated, for the first time a bivalent fully antagonist anti-c-Met monoclonal antibody (Mab 224G11) that has been humanized as an IgG1 antibody (Mab h224G11). The humanized Mab exhibits a high affinity for the receptor, blocks HGF binding, inhibits c-Met phosphorylation and c-Met dimerization. These effects are presumably responsible for the inhibition of the major functions of c-Met including cell proliferation, migration, invasion but also cell scattering, morphogenesis and angiogenesis, observed in vitro with different cell lines. The present results indicate that the h224G11 humanized antibody is powerful in vitro for impairing the major biological functions of c-Met. The results strongly suggest that h224G11 has a great potential for in vivo activity (see abstract 2) and for cancer therapy.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 835.